nodes	percent_of_prediction	percent_of_DWPC	metapath
Magnesium salicylate—PTGS2—urinary bladder cancer	0.527	1	CbGaD
Magnesium salicylate—PTGS2—Cisplatin—urinary bladder cancer	0.0849	0.252	CbGbCtD
Magnesium salicylate—PTGS2—Etoposide—urinary bladder cancer	0.0834	0.248	CbGbCtD
Magnesium salicylate—PTGS1—Etoposide—urinary bladder cancer	0.0705	0.209	CbGbCtD
Magnesium salicylate—ALB—Fluorouracil—urinary bladder cancer	0.063	0.187	CbGbCtD
Magnesium salicylate—ALB—Methotrexate—urinary bladder cancer	0.0348	0.103	CbGbCtD
Magnesium salicylate—Carbamazepine—UGT2B7—urinary bladder cancer	0.00117	0.175	CrCbGaD
Magnesium salicylate—Trisalicylate-choline—PTGS2—urinary bladder cancer	0.00115	0.173	CrCbGaD
Magnesium salicylate—Olsalazine—PPARG—urinary bladder cancer	0.00113	0.17	CrCbGaD
Magnesium salicylate—Deafness—Thiotepa—urinary bladder cancer	0.000899	0.00909	CcSEcCtD
Magnesium salicylate—Skin exfoliation—Gemcitabine—urinary bladder cancer	0.000889	0.009	CcSEcCtD
Magnesium salicylate—Oesophagitis—Fluorouracil—urinary bladder cancer	0.000837	0.00847	CcSEcCtD
Magnesium salicylate—Skin exfoliation—Cisplatin—urinary bladder cancer	0.000829	0.00839	CcSEcCtD
Magnesium salicylate—Pruritus—Valrubicin—urinary bladder cancer	0.000807	0.00816	CcSEcCtD
Magnesium salicylate—Body temperature decreased—Epirubicin—urinary bladder cancer	0.000795	0.00805	CcSEcCtD
Magnesium salicylate—Hypothermia—Epirubicin—urinary bladder cancer	0.000795	0.00805	CcSEcCtD
Magnesium salicylate—Confusional state—Mitomycin—urinary bladder cancer	0.000792	0.00801	CcSEcCtD
Magnesium salicylate—Oedema—Mitomycin—urinary bladder cancer	0.000786	0.00795	CcSEcCtD
Magnesium salicylate—Diarrhoea—Valrubicin—urinary bladder cancer	0.00078	0.00789	CcSEcCtD
Magnesium salicylate—Shock—Mitomycin—urinary bladder cancer	0.000773	0.00782	CcSEcCtD
Magnesium salicylate—Gastric ulcer—Epirubicin—urinary bladder cancer	0.000767	0.00776	CcSEcCtD
Magnesium salicylate—Skin exfoliation—Etoposide—urinary bladder cancer	0.000759	0.00768	CcSEcCtD
Magnesium salicylate—Deafness—Gemcitabine—urinary bladder cancer	0.000756	0.00765	CcSEcCtD
Magnesium salicylate—Dizziness—Valrubicin—urinary bladder cancer	0.000754	0.00763	CcSEcCtD
Magnesium salicylate—Anorexia—Mitomycin—urinary bladder cancer	0.000749	0.00757	CcSEcCtD
Magnesium salicylate—Body temperature decreased—Doxorubicin—urinary bladder cancer	0.000736	0.00744	CcSEcCtD
Magnesium salicylate—Hypothermia—Doxorubicin—urinary bladder cancer	0.000736	0.00744	CcSEcCtD
Magnesium salicylate—Oesophagitis—Etoposide—urinary bladder cancer	0.000727	0.00735	CcSEcCtD
Magnesium salicylate—Vomiting—Valrubicin—urinary bladder cancer	0.000725	0.00733	CcSEcCtD
Magnesium salicylate—Rash—Valrubicin—urinary bladder cancer	0.000719	0.00727	CcSEcCtD
Magnesium salicylate—Dermatitis—Valrubicin—urinary bladder cancer	0.000718	0.00727	CcSEcCtD
Magnesium salicylate—Headache—Valrubicin—urinary bladder cancer	0.000714	0.00723	CcSEcCtD
Magnesium salicylate—Gastric ulcer—Doxorubicin—urinary bladder cancer	0.00071	0.00718	CcSEcCtD
Magnesium salicylate—Deafness—Cisplatin—urinary bladder cancer	0.000705	0.00713	CcSEcCtD
Magnesium salicylate—Salicylate-sodium—PTGS2—urinary bladder cancer	0.000698	0.105	CrCbGaD
Magnesium salicylate—Somnolence—Mitomycin—urinary bladder cancer	0.000698	0.00706	CcSEcCtD
Magnesium salicylate—Burning sensation—Methotrexate—urinary bladder cancer	0.000686	0.00694	CcSEcCtD
Magnesium salicylate—Decreased appetite—Mitomycin—urinary bladder cancer	0.000683	0.00691	CcSEcCtD
Magnesium salicylate—Ketoprofen—CXCL8—urinary bladder cancer	0.000681	0.102	CrCbGaD
Magnesium salicylate—Lethargy—Fluorouracil—urinary bladder cancer	0.000678	0.00686	CcSEcCtD
Magnesium salicylate—Nausea—Valrubicin—urinary bladder cancer	0.000677	0.00685	CcSEcCtD
Magnesium salicylate—Pain—Mitomycin—urinary bladder cancer	0.000672	0.0068	CcSEcCtD
Magnesium salicylate—Feeling abnormal—Mitomycin—urinary bladder cancer	0.000647	0.00655	CcSEcCtD
Magnesium salicylate—Burning sensation—Epirubicin—urinary bladder cancer	0.000642	0.00649	CcSEcCtD
Magnesium salicylate—Stupor—Methotrexate—urinary bladder cancer	0.000638	0.00646	CcSEcCtD
Magnesium salicylate—Weight increased—Thiotepa—urinary bladder cancer	0.000632	0.0064	CcSEcCtD
Magnesium salicylate—Burning sensation—Doxorubicin—urinary bladder cancer	0.000594	0.00601	CcSEcCtD
Magnesium salicylate—Epistaxis—Thiotepa—urinary bladder cancer	0.000584	0.00591	CcSEcCtD
Magnesium salicylate—Hallucination—Thiotepa—urinary bladder cancer	0.000553	0.0056	CcSEcCtD
Magnesium salicylate—Stinging—Epirubicin—urinary bladder cancer	0.00055	0.00557	CcSEcCtD
Magnesium salicylate—Diarrhoea—Mitomycin—urinary bladder cancer	0.000538	0.00544	CcSEcCtD
Magnesium salicylate—Abdominal discomfort—Cisplatin—urinary bladder cancer	0.000522	0.00528	CcSEcCtD
Magnesium salicylate—Dizziness—Mitomycin—urinary bladder cancer	0.00052	0.00526	CcSEcCtD
Magnesium salicylate—Tinnitus—Thiotepa—urinary bladder cancer	0.000519	0.00524	CcSEcCtD
Magnesium salicylate—Stinging—Doxorubicin—urinary bladder cancer	0.000509	0.00515	CcSEcCtD
Magnesium salicylate—Sweating—Gemcitabine—urinary bladder cancer	0.0005	0.00505	CcSEcCtD
Magnesium salicylate—Vomiting—Mitomycin—urinary bladder cancer	0.0005	0.00505	CcSEcCtD
Magnesium salicylate—Rash—Mitomycin—urinary bladder cancer	0.000495	0.00501	CcSEcCtD
Magnesium salicylate—Dermatitis—Mitomycin—urinary bladder cancer	0.000495	0.00501	CcSEcCtD
Magnesium salicylate—Headache—Mitomycin—urinary bladder cancer	0.000492	0.00498	CcSEcCtD
Magnesium salicylate—Nepafenac—PTGS2—urinary bladder cancer	0.00049	0.0736	CrCbGaD
Magnesium salicylate—Hypocalcaemia—Epirubicin—urinary bladder cancer	0.000487	0.00493	CcSEcCtD
Magnesium salicylate—Erythema—Thiotepa—urinary bladder cancer	0.000484	0.0049	CcSEcCtD
Magnesium salicylate—Epistaxis—Fluorouracil—urinary bladder cancer	0.000483	0.00489	CcSEcCtD
Magnesium salicylate—Olsalazine—PTGS2—urinary bladder cancer	0.000479	0.0719	CrCbGaD
Magnesium salicylate—Nausea—Mitomycin—urinary bladder cancer	0.000467	0.00472	CcSEcCtD
Magnesium salicylate—Depressed level of consciousness—Methotrexate—urinary bladder cancer	0.00046	0.00465	CcSEcCtD
Magnesium salicylate—Skin exfoliation—Methotrexate—urinary bladder cancer	0.000455	0.0046	CcSEcCtD
Magnesium salicylate—Hypocalcaemia—Doxorubicin—urinary bladder cancer	0.000451	0.00456	CcSEcCtD
Magnesium salicylate—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.000442	0.00447	CcSEcCtD
Magnesium salicylate—Ecchymosis—Methotrexate—urinary bladder cancer	0.000431	0.00436	CcSEcCtD
Magnesium salicylate—Skin exfoliation—Epirubicin—urinary bladder cancer	0.000426	0.00431	CcSEcCtD
Magnesium salicylate—Oesophagitis—Epirubicin—urinary bladder cancer	0.000407	0.00412	CcSEcCtD
Magnesium salicylate—Erythema—Gemcitabine—urinary bladder cancer	0.000407	0.00412	CcSEcCtD
Magnesium salicylate—Salsalate—PTGS2—urinary bladder cancer	0.000407	0.0611	CrCbGaD
Magnesium salicylate—Tinnitus—Cisplatin—urinary bladder cancer	0.000407	0.00411	CcSEcCtD
Magnesium salicylate—Flushing—Cisplatin—urinary bladder cancer	0.000405	0.00409	CcSEcCtD
Magnesium salicylate—Ecchymosis—Epirubicin—urinary bladder cancer	0.000403	0.00408	CcSEcCtD
Magnesium salicylate—Erythema—Fluorouracil—urinary bladder cancer	0.0004	0.00405	CcSEcCtD
Magnesium salicylate—Confusional state—Thiotepa—urinary bladder cancer	0.000398	0.00403	CcSEcCtD
Magnesium salicylate—Skin exfoliation—Doxorubicin—urinary bladder cancer	0.000394	0.00398	CcSEcCtD
Magnesium salicylate—Erythema—Cisplatin—urinary bladder cancer	0.00038	0.00384	CcSEcCtD
Magnesium salicylate—Erythema multiforme—Etoposide—urinary bladder cancer	0.000378	0.00382	CcSEcCtD
Magnesium salicylate—Oesophagitis—Doxorubicin—urinary bladder cancer	0.000377	0.00381	CcSEcCtD
Magnesium salicylate—Anorexia—Thiotepa—urinary bladder cancer	0.000377	0.00381	CcSEcCtD
Magnesium salicylate—Ecchymosis—Doxorubicin—urinary bladder cancer	0.000373	0.00377	CcSEcCtD
Magnesium salicylate—Flushing—Etoposide—urinary bladder cancer	0.000371	0.00375	CcSEcCtD
Magnesium salicylate—Lethargy—Methotrexate—urinary bladder cancer	0.000353	0.00357	CcSEcCtD
Magnesium salicylate—Somnolence—Thiotepa—urinary bladder cancer	0.000351	0.00355	CcSEcCtD
Magnesium salicylate—Dyspepsia—Thiotepa—urinary bladder cancer	0.000348	0.00352	CcSEcCtD
Magnesium salicylate—Decreased appetite—Thiotepa—urinary bladder cancer	0.000343	0.00347	CcSEcCtD
Magnesium salicylate—Dysgeusia—Etoposide—urinary bladder cancer	0.000341	0.00344	CcSEcCtD
Magnesium salicylate—Pain—Thiotepa—urinary bladder cancer	0.000338	0.00342	CcSEcCtD
Magnesium salicylate—Constipation—Thiotepa—urinary bladder cancer	0.000338	0.00342	CcSEcCtD
Magnesium salicylate—Oedema—Gemcitabine—urinary bladder cancer	0.000332	0.00336	CcSEcCtD
Magnesium salicylate—Lethargy—Epirubicin—urinary bladder cancer	0.00033	0.00334	CcSEcCtD
Magnesium salicylate—Confusional state—Fluorouracil—urinary bladder cancer	0.000329	0.00333	CcSEcCtD
Magnesium salicylate—Oedema—Fluorouracil—urinary bladder cancer	0.000327	0.00331	CcSEcCtD
Magnesium salicylate—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000326	0.00329	CcSEcCtD
Magnesium salicylate—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000321	0.00325	CcSEcCtD
Magnesium salicylate—Anorexia—Gemcitabine—urinary bladder cancer	0.000317	0.0032	CcSEcCtD
Magnesium salicylate—Urticaria—Thiotepa—urinary bladder cancer	0.000314	0.00317	CcSEcCtD
Magnesium salicylate—Anorexia—Fluorouracil—urinary bladder cancer	0.000311	0.00315	CcSEcCtD
Magnesium salicylate—Hypotension—Gemcitabine—urinary bladder cancer	0.000311	0.00314	CcSEcCtD
Magnesium salicylate—Oedema—Cisplatin—urinary bladder cancer	0.00031	0.00313	CcSEcCtD
Magnesium salicylate—Lethargy—Doxorubicin—urinary bladder cancer	0.000306	0.00309	CcSEcCtD
Magnesium salicylate—Hypotension—Fluorouracil—urinary bladder cancer	0.000305	0.00309	CcSEcCtD
Magnesium salicylate—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000299	0.00303	CcSEcCtD
Magnesium salicylate—Asthma—Methotrexate—urinary bladder cancer	0.000299	0.00302	CcSEcCtD
Magnesium salicylate—Abdominal pain upper—Epirubicin—urinary bladder cancer	0.000296	0.00299	CcSEcCtD
Magnesium salicylate—Somnolence—Gemcitabine—urinary bladder cancer	0.000295	0.00299	CcSEcCtD
Magnesium salicylate—Anorexia—Cisplatin—urinary bladder cancer	0.000295	0.00299	CcSEcCtD
Magnesium salicylate—Somnolence—Fluorouracil—urinary bladder cancer	0.000291	0.00294	CcSEcCtD
Magnesium salicylate—Hypotension—Cisplatin—urinary bladder cancer	0.000289	0.00293	CcSEcCtD
Magnesium salicylate—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000289	0.00292	CcSEcCtD
Magnesium salicylate—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000288	0.00291	CcSEcCtD
Magnesium salicylate—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000287	0.0029	CcSEcCtD
Magnesium salicylate—Confusional state—Etoposide—urinary bladder cancer	0.000286	0.00289	CcSEcCtD
Magnesium salicylate—Constipation—Gemcitabine—urinary bladder cancer	0.000284	0.00287	CcSEcCtD
Magnesium salicylate—Pain—Gemcitabine—urinary bladder cancer	0.000284	0.00287	CcSEcCtD
Magnesium salicylate—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000284	0.00287	CcSEcCtD
Magnesium salicylate—Asthma—Epirubicin—urinary bladder cancer	0.00028	0.00283	CcSEcCtD
Magnesium salicylate—Pruritus—Thiotepa—urinary bladder cancer	0.00028	0.00283	CcSEcCtD
Magnesium salicylate—Pain—Fluorouracil—urinary bladder cancer	0.000279	0.00283	CcSEcCtD
Magnesium salicylate—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000274	0.00278	CcSEcCtD
Magnesium salicylate—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000274	0.00277	CcSEcCtD
Magnesium salicylate—Abdominal pain upper—Doxorubicin—urinary bladder cancer	0.000274	0.00277	CcSEcCtD
Magnesium salicylate—Anorexia—Etoposide—urinary bladder cancer	0.000271	0.00274	CcSEcCtD
Magnesium salicylate—Diarrhoea—Thiotepa—urinary bladder cancer	0.00027	0.00273	CcSEcCtD
Magnesium salicylate—Decreased appetite—Cisplatin—urinary bladder cancer	0.000269	0.00272	CcSEcCtD
Magnesium salicylate—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000269	0.00272	CcSEcCtD
Magnesium salicylate—Drowsiness—Methotrexate—urinary bladder cancer	0.000267	0.0027	CcSEcCtD
Magnesium salicylate—Hypotension—Etoposide—urinary bladder cancer	0.000265	0.00268	CcSEcCtD
Magnesium salicylate—Pain—Cisplatin—urinary bladder cancer	0.000265	0.00268	CcSEcCtD
Magnesium salicylate—Dizziness—Thiotepa—urinary bladder cancer	0.000261	0.00264	CcSEcCtD
Magnesium salicylate—Urticaria—Fluorouracil—urinary bladder cancer	0.00026	0.00263	CcSEcCtD
Magnesium salicylate—Asthma—Doxorubicin—urinary bladder cancer	0.000259	0.00262	CcSEcCtD
Magnesium salicylate—Sweating—Methotrexate—urinary bladder cancer	0.000256	0.00258	CcSEcCtD
Magnesium salicylate—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000255	0.00258	CcSEcCtD
Magnesium salicylate—Weight increased—Epirubicin—urinary bladder cancer	0.000255	0.00258	CcSEcCtD
Magnesium salicylate—Somnolence—Etoposide—urinary bladder cancer	0.000252	0.00255	CcSEcCtD
Magnesium salicylate—Epistaxis—Methotrexate—urinary bladder cancer	0.000251	0.00254	CcSEcCtD
Magnesium salicylate—Vomiting—Thiotepa—urinary bladder cancer	0.000251	0.00254	CcSEcCtD
Magnesium salicylate—Salicylic acid—PTGS2—urinary bladder cancer	0.00025	0.0376	CrCbGaD
Magnesium salicylate—Drowsiness—Epirubicin—urinary bladder cancer	0.000249	0.00252	CcSEcCtD
Magnesium salicylate—Rash—Thiotepa—urinary bladder cancer	0.000249	0.00252	CcSEcCtD
Magnesium salicylate—Dermatitis—Thiotepa—urinary bladder cancer	0.000249	0.00252	CcSEcCtD
Magnesium salicylate—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—urinary bladder cancer	0.000248	0.0081	CbGpPWpGaD
Magnesium salicylate—Headache—Thiotepa—urinary bladder cancer	0.000248	0.0025	CcSEcCtD
Magnesium salicylate—Decreased appetite—Etoposide—urinary bladder cancer	0.000247	0.0025	CcSEcCtD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—MPO—urinary bladder cancer	0.000245	0.008	CbGpPWpGaD
Magnesium salicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—ESR1—urinary bladder cancer	0.000243	0.00792	CbGpPWpGaD
Magnesium salicylate—Pain—Etoposide—urinary bladder cancer	0.000243	0.00245	CcSEcCtD
Magnesium salicylate—Constipation—Etoposide—urinary bladder cancer	0.000243	0.00245	CcSEcCtD
Magnesium salicylate—PTGS1—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000242	0.00788	CbGpPWpGaD
Magnesium salicylate—ALB—Folate Metabolism—MPO—urinary bladder cancer	0.000241	0.00785	CbGpPWpGaD
Magnesium salicylate—Hepatitis—Methotrexate—urinary bladder cancer	0.000239	0.00242	CcSEcCtD
Magnesium salicylate—Sweating—Epirubicin—urinary bladder cancer	0.000239	0.00242	CcSEcCtD
Magnesium salicylate—PTGS2—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000236	0.0077	CbGpPWpGaD
Magnesium salicylate—Weight increased—Doxorubicin—urinary bladder cancer	0.000236	0.00238	CcSEcCtD
Magnesium salicylate—Epistaxis—Epirubicin—urinary bladder cancer	0.000235	0.00238	CcSEcCtD
Magnesium salicylate—Pruritus—Gemcitabine—urinary bladder cancer	0.000235	0.00238	CcSEcCtD
Magnesium salicylate—Nausea—Thiotepa—urinary bladder cancer	0.000235	0.00237	CcSEcCtD
Magnesium salicylate—Feeling abnormal—Etoposide—urinary bladder cancer	0.000234	0.00237	CcSEcCtD
Magnesium salicylate—Pruritus—Fluorouracil—urinary bladder cancer	0.000231	0.00234	CcSEcCtD
Magnesium salicylate—Drowsiness—Doxorubicin—urinary bladder cancer	0.000231	0.00233	CcSEcCtD
Magnesium salicylate—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000227	0.0023	CcSEcCtD
Magnesium salicylate—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000226	0.00229	CcSEcCtD
Magnesium salicylate—Urticaria—Etoposide—urinary bladder cancer	0.000225	0.00228	CcSEcCtD
Magnesium salicylate—Hepatitis—Epirubicin—urinary bladder cancer	0.000224	0.00226	CcSEcCtD
Magnesium salicylate—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000224	0.00226	CcSEcCtD
Magnesium salicylate—Tinnitus—Methotrexate—urinary bladder cancer	0.000223	0.00226	CcSEcCtD
Magnesium salicylate—PTGS2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000223	0.00725	CbGpPWpGaD
Magnesium salicylate—Sweating—Doxorubicin—urinary bladder cancer	0.000221	0.00224	CcSEcCtD
Magnesium salicylate—PTGS1—Biological oxidations—NAT2—urinary bladder cancer	0.000221	0.00719	CbGpPWpGaD
Magnesium salicylate—Epistaxis—Doxorubicin—urinary bladder cancer	0.000218	0.0022	CcSEcCtD
Magnesium salicylate—Dizziness—Fluorouracil—urinary bladder cancer	0.000216	0.00219	CcSEcCtD
Magnesium salicylate—Diarrhoea—Cisplatin—urinary bladder cancer	0.000212	0.00214	CcSEcCtD
Magnesium salicylate—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000212	0.00214	CcSEcCtD
Magnesium salicylate—Vomiting—Gemcitabine—urinary bladder cancer	0.000211	0.00214	CcSEcCtD
Magnesium salicylate—Rash—Gemcitabine—urinary bladder cancer	0.00021	0.00212	CcSEcCtD
Magnesium salicylate—Dermatitis—Gemcitabine—urinary bladder cancer	0.000209	0.00212	CcSEcCtD
Magnesium salicylate—Tinnitus—Epirubicin—urinary bladder cancer	0.000209	0.00211	CcSEcCtD
Magnesium salicylate—Erythema—Methotrexate—urinary bladder cancer	0.000208	0.00211	CcSEcCtD
Magnesium salicylate—Headache—Gemcitabine—urinary bladder cancer	0.000208	0.00211	CcSEcCtD
Magnesium salicylate—Flushing—Epirubicin—urinary bladder cancer	0.000208	0.0021	CcSEcCtD
Magnesium salicylate—Vomiting—Fluorouracil—urinary bladder cancer	0.000208	0.0021	CcSEcCtD
Magnesium salicylate—Hepatitis—Doxorubicin—urinary bladder cancer	0.000207	0.0021	CcSEcCtD
Magnesium salicylate—Rash—Fluorouracil—urinary bladder cancer	0.000206	0.00208	CcSEcCtD
Magnesium salicylate—Dermatitis—Fluorouracil—urinary bladder cancer	0.000206	0.00208	CcSEcCtD
Magnesium salicylate—Headache—Fluorouracil—urinary bladder cancer	0.000205	0.00207	CcSEcCtD
Magnesium salicylate—Dysgeusia—Methotrexate—urinary bladder cancer	0.000204	0.00206	CcSEcCtD
Magnesium salicylate—Pruritus—Etoposide—urinary bladder cancer	0.000201	0.00203	CcSEcCtD
Magnesium salicylate—Ketoprofen—PTGS2—urinary bladder cancer	0.000199	0.0298	CrCbGaD
Magnesium salicylate—Nausea—Gemcitabine—urinary bladder cancer	0.000197	0.002	CcSEcCtD
Magnesium salicylate—Vomiting—Cisplatin—urinary bladder cancer	0.000197	0.00199	CcSEcCtD
Magnesium salicylate—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000196	0.00198	CcSEcCtD
Magnesium salicylate—Rash—Cisplatin—urinary bladder cancer	0.000195	0.00198	CcSEcCtD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000195	0.00636	CbGpPWpGaD
Magnesium salicylate—Dermatitis—Cisplatin—urinary bladder cancer	0.000195	0.00197	CcSEcCtD
Magnesium salicylate—Erythema—Epirubicin—urinary bladder cancer	0.000195	0.00197	CcSEcCtD
Magnesium salicylate—Diarrhoea—Etoposide—urinary bladder cancer	0.000194	0.00196	CcSEcCtD
Magnesium salicylate—Nausea—Fluorouracil—urinary bladder cancer	0.000194	0.00196	CcSEcCtD
Magnesium salicylate—Tinnitus—Doxorubicin—urinary bladder cancer	0.000193	0.00195	CcSEcCtD
Magnesium salicylate—Flushing—Doxorubicin—urinary bladder cancer	0.000192	0.00194	CcSEcCtD
Magnesium salicylate—PTGS2—Overview of nanoparticle effects—TNF—urinary bladder cancer	0.000192	0.00625	CbGpPWpGaD
Magnesium salicylate—ALB—Selenium Micronutrient Network—MPO—urinary bladder cancer	0.000191	0.00623	CbGpPWpGaD
Magnesium salicylate—Dysgeusia—Epirubicin—urinary bladder cancer	0.000191	0.00193	CcSEcCtD
Magnesium salicylate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—urinary bladder cancer	0.000188	0.00612	CbGpPWpGaD
Magnesium salicylate—Dizziness—Etoposide—urinary bladder cancer	0.000188	0.0019	CcSEcCtD
Magnesium salicylate—PTGS1—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000187	0.00609	CbGpPWpGaD
Magnesium salicylate—ALB—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000186	0.00606	CbGpPWpGaD
Magnesium salicylate—ALB—Vitamin B12 Metabolism—SOD2—urinary bladder cancer	0.000186	0.00606	CbGpPWpGaD
Magnesium salicylate—Nausea—Cisplatin—urinary bladder cancer	0.000184	0.00186	CcSEcCtD
Magnesium salicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—urinary bladder cancer	0.000183	0.00598	CbGpPWpGaD
Magnesium salicylate—Vomiting—Etoposide—urinary bladder cancer	0.00018	0.00183	CcSEcCtD
Magnesium salicylate—Erythema—Doxorubicin—urinary bladder cancer	0.00018	0.00182	CcSEcCtD
Magnesium salicylate—Rash—Etoposide—urinary bladder cancer	0.000179	0.00181	CcSEcCtD
Magnesium salicylate—Dermatitis—Etoposide—urinary bladder cancer	0.000179	0.00181	CcSEcCtD
Magnesium salicylate—PTGS1—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000178	0.00581	CbGpPWpGaD
Magnesium salicylate—Headache—Etoposide—urinary bladder cancer	0.000178	0.0018	CcSEcCtD
Magnesium salicylate—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000177	0.00179	CcSEcCtD
Magnesium salicylate—PTGS1—Biological oxidations—HPGDS—urinary bladder cancer	0.000176	0.00575	CbGpPWpGaD
Magnesium salicylate—Confusional state—Methotrexate—urinary bladder cancer	0.000171	0.00173	CcSEcCtD
Magnesium salicylate—PTGS1—Biological oxidations—GSTT1—urinary bladder cancer	0.000171	0.00558	CbGpPWpGaD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.00017	0.00555	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000169	0.0055	CbGpPWpGaD
Magnesium salicylate—Nausea—Etoposide—urinary bladder cancer	0.000169	0.00171	CcSEcCtD
Magnesium salicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—urinary bladder cancer	0.000167	0.00543	CbGpPWpGaD
Magnesium salicylate—PTGS1—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000165	0.00538	CbGpPWpGaD
Magnesium salicylate—PTGS1—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000165	0.00537	CbGpPWpGaD
Magnesium salicylate—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000164	0.00166	CcSEcCtD
Magnesium salicylate—ALB—Vitamin B12 Metabolism—MTHFR—urinary bladder cancer	0.000164	0.00533	CbGpPWpGaD
Magnesium salicylate—Anorexia—Methotrexate—urinary bladder cancer	0.000162	0.00164	CcSEcCtD
Magnesium salicylate—Confusional state—Epirubicin—urinary bladder cancer	0.00016	0.00162	CcSEcCtD
Magnesium salicylate—Oedema—Epirubicin—urinary bladder cancer	0.000159	0.00161	CcSEcCtD
Magnesium salicylate—Hypotension—Methotrexate—urinary bladder cancer	0.000159	0.00161	CcSEcCtD
Magnesium salicylate—Shock—Epirubicin—urinary bladder cancer	0.000157	0.00158	CcSEcCtD
Magnesium salicylate—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000154	0.00156	CcSEcCtD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—GSTM1—urinary bladder cancer	0.000154	0.005	CbGpPWpGaD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—NCOR1—urinary bladder cancer	0.000154	0.005	CbGpPWpGaD
Magnesium salicylate—Anorexia—Epirubicin—urinary bladder cancer	0.000152	0.00153	CcSEcCtD
Magnesium salicylate—ALB—Folate Metabolism—SOD2—urinary bladder cancer	0.000151	0.00493	CbGpPWpGaD
Magnesium salicylate—Somnolence—Methotrexate—urinary bladder cancer	0.000151	0.00153	CcSEcCtD
Magnesium salicylate—Dyspepsia—Methotrexate—urinary bladder cancer	0.00015	0.00151	CcSEcCtD
Magnesium salicylate—Hypotension—Epirubicin—urinary bladder cancer	0.000149	0.0015	CcSEcCtD
Magnesium salicylate—PTGS2—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.000148	0.00484	CbGpPWpGaD
Magnesium salicylate—Confusional state—Doxorubicin—urinary bladder cancer	0.000148	0.0015	CcSEcCtD
Magnesium salicylate—Decreased appetite—Methotrexate—urinary bladder cancer	0.000148	0.00149	CcSEcCtD
Magnesium salicylate—Oedema—Doxorubicin—urinary bladder cancer	0.000147	0.00149	CcSEcCtD
Magnesium salicylate—Pain—Methotrexate—urinary bladder cancer	0.000145	0.00147	CcSEcCtD
Magnesium salicylate—Shock—Doxorubicin—urinary bladder cancer	0.000145	0.00146	CcSEcCtD
Magnesium salicylate—ALB—Folate Metabolism—GPX1—urinary bladder cancer	0.000144	0.0047	CbGpPWpGaD
Magnesium salicylate—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000142	0.00144	CcSEcCtD
Magnesium salicylate—PTGS2—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000142	0.00462	CbGpPWpGaD
Magnesium salicylate—Somnolence—Epirubicin—urinary bladder cancer	0.000141	0.00143	CcSEcCtD
Magnesium salicylate—Anorexia—Doxorubicin—urinary bladder cancer	0.00014	0.00142	CcSEcCtD
Magnesium salicylate—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00014	0.00142	CcSEcCtD
Magnesium salicylate—Dyspepsia—Epirubicin—urinary bladder cancer	0.00014	0.00142	CcSEcCtD
Magnesium salicylate—Decreased appetite—Epirubicin—urinary bladder cancer	0.000138	0.0014	CcSEcCtD
Magnesium salicylate—Hypotension—Doxorubicin—urinary bladder cancer	0.000138	0.00139	CcSEcCtD
Magnesium salicylate—Constipation—Epirubicin—urinary bladder cancer	0.000136	0.00138	CcSEcCtD
Magnesium salicylate—Pain—Epirubicin—urinary bladder cancer	0.000136	0.00138	CcSEcCtD
Magnesium salicylate—Urticaria—Methotrexate—urinary bladder cancer	0.000135	0.00137	CcSEcCtD
Magnesium salicylate—ALB—Folate Metabolism—MTHFR—urinary bladder cancer	0.000133	0.00434	CbGpPWpGaD
Magnesium salicylate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—urinary bladder cancer	0.000132	0.0043	CbGpPWpGaD
Magnesium salicylate—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000131	0.00133	CcSEcCtD
Magnesium salicylate—Somnolence—Doxorubicin—urinary bladder cancer	0.000131	0.00132	CcSEcCtD
Magnesium salicylate—PTGS2—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000131	0.00426	CbGpPWpGaD
Magnesium salicylate—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00013	0.00131	CcSEcCtD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000129	0.0042	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000128	0.00417	CbGpPWpGaD
Magnesium salicylate—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000128	0.00129	CcSEcCtD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000127	0.00415	CbGpPWpGaD
Magnesium salicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—urinary bladder cancer	0.000127	0.00414	CbGpPWpGaD
Magnesium salicylate—Urticaria—Epirubicin—urinary bladder cancer	0.000126	0.00128	CcSEcCtD
Magnesium salicylate—Pain—Doxorubicin—urinary bladder cancer	0.000126	0.00127	CcSEcCtD
Magnesium salicylate—Constipation—Doxorubicin—urinary bladder cancer	0.000126	0.00127	CcSEcCtD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000122	0.00399	CbGpPWpGaD
Magnesium salicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—urinary bladder cancer	0.000121	0.00396	CbGpPWpGaD
Magnesium salicylate—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000121	0.00123	CcSEcCtD
Magnesium salicylate—Pruritus—Methotrexate—urinary bladder cancer	0.00012	0.00122	CcSEcCtD
Magnesium salicylate—ALB—Selenium Micronutrient Network—SOD2—urinary bladder cancer	0.00012	0.00391	CbGpPWpGaD
Magnesium salicylate—PTGS1—Biological oxidations—GSTP1—urinary bladder cancer	0.000119	0.00387	CbGpPWpGaD
Magnesium salicylate—Urticaria—Doxorubicin—urinary bladder cancer	0.000117	0.00118	CcSEcCtD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000117	0.0038	CbGpPWpGaD
Magnesium salicylate—Diarrhoea—Methotrexate—urinary bladder cancer	0.000116	0.00118	CcSEcCtD
Magnesium salicylate—ALB—Selenium Micronutrient Network—GPX1—urinary bladder cancer	0.000115	0.00373	CbGpPWpGaD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000113	0.00369	CbGpPWpGaD
Magnesium salicylate—Pruritus—Epirubicin—urinary bladder cancer	0.000113	0.00114	CcSEcCtD
Magnesium salicylate—Dizziness—Methotrexate—urinary bladder cancer	0.000112	0.00114	CcSEcCtD
Magnesium salicylate—PTGS1—Biological oxidations—GSTM1—urinary bladder cancer	0.000109	0.00355	CbGpPWpGaD
Magnesium salicylate—Diarrhoea—Epirubicin—urinary bladder cancer	0.000109	0.0011	CcSEcCtD
Magnesium salicylate—Vomiting—Methotrexate—urinary bladder cancer	0.000108	0.00109	CcSEcCtD
Magnesium salicylate—Rash—Methotrexate—urinary bladder cancer	0.000107	0.00108	CcSEcCtD
Magnesium salicylate—Dermatitis—Methotrexate—urinary bladder cancer	0.000107	0.00108	CcSEcCtD
Magnesium salicylate—Headache—Methotrexate—urinary bladder cancer	0.000106	0.00108	CcSEcCtD
Magnesium salicylate—ALB—Selenium Micronutrient Network—MTHFR—urinary bladder cancer	0.000106	0.00345	CbGpPWpGaD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—CREBBP—urinary bladder cancer	0.000106	0.00344	CbGpPWpGaD
Magnesium salicylate—Dizziness—Epirubicin—urinary bladder cancer	0.000105	0.00106	CcSEcCtD
Magnesium salicylate—PTGS1—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	0.000105	0.00342	CbGpPWpGaD
Magnesium salicylate—Pruritus—Doxorubicin—urinary bladder cancer	0.000104	0.00105	CcSEcCtD
Magnesium salicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—urinary bladder cancer	0.000104	0.00338	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000103	0.00336	CbGpPWpGaD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000102	0.00331	CbGpPWpGaD
Magnesium salicylate—Vomiting—Epirubicin—urinary bladder cancer	0.000101	0.00102	CcSEcCtD
Magnesium salicylate—PTGS2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000101	0.00329	CbGpPWpGaD
Magnesium salicylate—Nausea—Methotrexate—urinary bladder cancer	0.000101	0.00102	CcSEcCtD
Magnesium salicylate—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000101	0.00102	CcSEcCtD
Magnesium salicylate—Rash—Epirubicin—urinary bladder cancer	0.0001	0.00101	CcSEcCtD
Magnesium salicylate—Dermatitis—Epirubicin—urinary bladder cancer	0.0001	0.00101	CcSEcCtD
Magnesium salicylate—Headache—Epirubicin—urinary bladder cancer	9.97e-05	0.00101	CcSEcCtD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	9.93e-05	0.00324	CbGpPWpGaD
Magnesium salicylate—Dizziness—Doxorubicin—urinary bladder cancer	9.73e-05	0.000985	CcSEcCtD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	9.46e-05	0.00308	CbGpPWpGaD
Magnesium salicylate—Nausea—Epirubicin—urinary bladder cancer	9.45e-05	0.000956	CcSEcCtD
Magnesium salicylate—ALB—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	9.45e-05	0.00308	CbGpPWpGaD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	9.38e-05	0.00306	CbGpPWpGaD
Magnesium salicylate—Vomiting—Doxorubicin—urinary bladder cancer	9.36e-05	0.000947	CcSEcCtD
Magnesium salicylate—Rash—Doxorubicin—urinary bladder cancer	9.28e-05	0.000939	CcSEcCtD
Magnesium salicylate—Dermatitis—Doxorubicin—urinary bladder cancer	9.27e-05	0.000938	CcSEcCtD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	9.26e-05	0.00302	CbGpPWpGaD
Magnesium salicylate—PTGS2—Spinal Cord Injury—CDK4—urinary bladder cancer	9.23e-05	0.00301	CbGpPWpGaD
Magnesium salicylate—Headache—Doxorubicin—urinary bladder cancer	9.22e-05	0.000933	CcSEcCtD
Magnesium salicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—urinary bladder cancer	8.85e-05	0.00288	CbGpPWpGaD
Magnesium salicylate—ALB—Platelet degranulation—IGF1—urinary bladder cancer	8.78e-05	0.00286	CbGpPWpGaD
Magnesium salicylate—Nausea—Doxorubicin—urinary bladder cancer	8.74e-05	0.000884	CcSEcCtD
Magnesium salicylate—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—urinary bladder cancer	8.37e-05	0.00273	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	8.2e-05	0.00267	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	8.18e-05	0.00267	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	8.05e-05	0.00262	CbGpPWpGaD
Magnesium salicylate—PTGS2—Spinal Cord Injury—RB1—urinary bladder cancer	8.02e-05	0.00261	CbGpPWpGaD
Magnesium salicylate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	7.98e-05	0.0026	CbGpPWpGaD
Magnesium salicylate—ALB—Folate Metabolism—IL2—urinary bladder cancer	7.87e-05	0.00256	CbGpPWpGaD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—CCND1—urinary bladder cancer	7.82e-05	0.00255	CbGpPWpGaD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	7.57e-05	0.00247	CbGpPWpGaD
Magnesium salicylate—PTGS2—Spinal Cord Injury—RHOA—urinary bladder cancer	7.29e-05	0.00237	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—GSTZ1—urinary bladder cancer	7.27e-05	0.00237	CbGpPWpGaD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—EP300—urinary bladder cancer	7.2e-05	0.00235	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	7.13e-05	0.00232	CbGpPWpGaD
Magnesium salicylate—PTGS1—Selenium Micronutrient Network—TNF—urinary bladder cancer	7.09e-05	0.00231	CbGpPWpGaD
Magnesium salicylate—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	7.05e-05	0.0023	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—GSTO2—urinary bladder cancer	6.89e-05	0.00224	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—NAT1—urinary bladder cancer	6.89e-05	0.00224	CbGpPWpGaD
Magnesium salicylate—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	6.83e-05	0.00223	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.78e-05	0.00221	CbGpPWpGaD
Magnesium salicylate—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	6.75e-05	0.0022	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—GSTO2—urinary bladder cancer	6.53e-05	0.00213	CbGpPWpGaD
Magnesium salicylate—PTGS2—Spinal Cord Injury—CXCL8—urinary bladder cancer	6.4e-05	0.00208	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	6.3e-05	0.00205	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—UGT2B7—urinary bladder cancer	6.3e-05	0.00205	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	6.28e-05	0.00205	CbGpPWpGaD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—MYC—urinary bladder cancer	6.27e-05	0.00204	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	6.25e-05	0.00204	CbGpPWpGaD
Magnesium salicylate—PTGS2—Spinal Cord Injury—IL2—urinary bladder cancer	6.11e-05	0.00199	CbGpPWpGaD
Magnesium salicylate—PTGS2—Spinal Cord Injury—CCND1—urinary bladder cancer	5.96e-05	0.00194	CbGpPWpGaD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—KRAS—urinary bladder cancer	5.8e-05	0.00189	CbGpPWpGaD
Magnesium salicylate—PTGS2—Spinal Cord Injury—MMP9—urinary bladder cancer	5.79e-05	0.00188	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—GSTZ1—urinary bladder cancer	5.77e-05	0.00188	CbGpPWpGaD
Magnesium salicylate—ALB—Folate Metabolism—TNF—urinary bladder cancer	5.73e-05	0.00187	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—CYP4B1—urinary bladder cancer	5.67e-05	0.00185	CbGpPWpGaD
Magnesium salicylate—PTGS2—Selenium Micronutrient Network—TNF—urinary bladder cancer	5.63e-05	0.00183	CbGpPWpGaD
Magnesium salicylate—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	5.57e-05	0.00181	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	5.48e-05	0.00179	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—GSTO2—urinary bladder cancer	5.47e-05	0.00178	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—NAT1—urinary bladder cancer	5.47e-05	0.00178	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	5.41e-05	0.00176	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.38e-05	0.00175	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—SLC19A1—urinary bladder cancer	5.36e-05	0.00175	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—PRSS3—urinary bladder cancer	5.22e-05	0.0017	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—SLC19A1—urinary bladder cancer	5.08e-05	0.00165	CbGpPWpGaD
Magnesium salicylate—ALB—Folate Metabolism—TP53—urinary bladder cancer	5.05e-05	0.00165	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—UGT2B7—urinary bladder cancer	5e-05	0.00163	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—PRSS3—urinary bladder cancer	4.95e-05	0.00161	CbGpPWpGaD
Magnesium salicylate—PTGS2—C-MYB transcription factor network—HRAS—urinary bladder cancer	4.93e-05	0.00161	CbGpPWpGaD
Magnesium salicylate—PTGS2—Spinal Cord Injury—MYC—urinary bladder cancer	4.78e-05	0.00156	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—HDAC4—urinary bladder cancer	4.72e-05	0.00154	CbGpPWpGaD
Magnesium salicylate—PTGS2—Spinal Cord Injury—EGFR—urinary bladder cancer	4.67e-05	0.00152	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—GSTZ1—urinary bladder cancer	4.67e-05	0.00152	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	4.59e-05	0.00149	CbGpPWpGaD
Magnesium salicylate—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	4.55e-05	0.00148	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—CYP4B1—urinary bladder cancer	4.5e-05	0.00147	CbGpPWpGaD
Magnesium salicylate—PTGS2—Spinal Cord Injury—TNF—urinary bladder cancer	4.45e-05	0.00145	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—GSTO2—urinary bladder cancer	4.42e-05	0.00144	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—NAT1—urinary bladder cancer	4.42e-05	0.00144	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.35e-05	0.00142	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—SLC19A1—urinary bladder cancer	4.25e-05	0.00139	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.19e-05	0.00136	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—TYMP—urinary bladder cancer	4.17e-05	0.00136	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—PRSS3—urinary bladder cancer	4.14e-05	0.00135	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.05e-05	0.00132	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—UGT2B7—urinary bladder cancer	4.05e-05	0.00132	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.01e-05	0.00131	CbGpPWpGaD
Magnesium salicylate—PTGS2—Spinal Cord Injury—TP53—urinary bladder cancer	3.93e-05	0.00128	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.92e-05	0.00128	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.91e-05	0.00127	CbGpPWpGaD
Magnesium salicylate—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	3.89e-05	0.00127	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—NAT2—urinary bladder cancer	3.77e-05	0.00123	CbGpPWpGaD
Magnesium salicylate—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.76e-05	0.00123	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—LIG1—urinary bladder cancer	3.75e-05	0.00122	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.73e-05	0.00122	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—CYP4B1—urinary bladder cancer	3.64e-05	0.00119	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.63e-05	0.00118	CbGpPWpGaD
Magnesium salicylate—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	3.57e-05	0.00116	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—IFNA2—urinary bladder cancer	3.47e-05	0.00113	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—SLC19A1—urinary bladder cancer	3.44e-05	0.00112	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—PRSS3—urinary bladder cancer	3.35e-05	0.00109	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.32e-05	0.00108	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—TYMP—urinary bladder cancer	3.31e-05	0.00108	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—RRM2—urinary bladder cancer	3.26e-05	0.00106	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.25e-05	0.00106	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.18e-05	0.00104	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.18e-05	0.00104	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.03e-05	0.000987	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—ENO2—urinary bladder cancer	3.02e-05	0.000983	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—HPGDS—urinary bladder cancer	3.02e-05	0.000983	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3e-05	0.000979	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3e-05	0.000977	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—NAT2—urinary bladder cancer	3e-05	0.000976	CbGpPWpGaD
Magnesium salicylate—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	2.99e-05	0.000975	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—GSTT1—urinary bladder cancer	2.93e-05	0.000954	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.88e-05	0.000939	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—ENO2—urinary bladder cancer	2.86e-05	0.000932	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—RBX1—urinary bladder cancer	2.71e-05	0.000883	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.69e-05	0.000876	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—TYMP—urinary bladder cancer	2.68e-05	0.000873	CbGpPWpGaD
Magnesium salicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.67e-05	0.00087	CbGpPWpGaD
Magnesium salicylate—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	2.61e-05	0.000851	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—RRM2—urinary bladder cancer	2.59e-05	0.000843	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.57e-05	0.000839	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—PLAU—urinary bladder cancer	2.46e-05	0.000803	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—NQO1—urinary bladder cancer	2.43e-05	0.000792	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—JAG1—urinary bladder cancer	2.43e-05	0.000791	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—NAT2—urinary bladder cancer	2.42e-05	0.00079	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—ENO2—urinary bladder cancer	2.4e-05	0.00078	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—HPGDS—urinary bladder cancer	2.4e-05	0.00078	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.38e-05	0.000776	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.36e-05	0.000769	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—GSTT1—urinary bladder cancer	2.32e-05	0.000757	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.29e-05	0.000745	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—RRM2—urinary bladder cancer	2.09e-05	0.000682	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.06e-05	0.000671	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—CREBBP—urinary bladder cancer	2.03e-05	0.000662	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—GSTP1—urinary bladder cancer	2.03e-05	0.000661	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—IGF1—urinary bladder cancer	2.01e-05	0.000654	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.96e-05	0.000639	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—HPGDS—urinary bladder cancer	1.94e-05	0.000631	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—ENO2—urinary bladder cancer	1.94e-05	0.000631	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.93e-05	0.000629	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.93e-05	0.000628	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—TYMS—urinary bladder cancer	1.89e-05	0.000614	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—GSTT1—urinary bladder cancer	1.88e-05	0.000612	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—NCOR1—urinary bladder cancer	1.86e-05	0.000607	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—GSTM1—urinary bladder cancer	1.86e-05	0.000607	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.85e-05	0.000603	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—RHOA—urinary bladder cancer	1.84e-05	0.000599	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—GPX1—urinary bladder cancer	1.79e-05	0.000582	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—NCOR1—urinary bladder cancer	1.77e-05	0.000576	CbGpPWpGaD
Magnesium salicylate—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.76e-05	0.000573	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—ERCC2—urinary bladder cancer	1.75e-05	0.000571	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—ERCC2—urinary bladder cancer	1.66e-05	0.000541	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.65e-05	0.000537	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.63e-05	0.000532	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—GSTP1—urinary bladder cancer	1.61e-05	0.000525	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—NQO1—urinary bladder cancer	1.56e-05	0.000509	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—MTHFR—urinary bladder cancer	1.56e-05	0.000509	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.56e-05	0.000508	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—TERT—urinary bladder cancer	1.56e-05	0.000507	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—IL2—urinary bladder cancer	1.54e-05	0.000503	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.52e-05	0.000494	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—TYMS—urinary bladder cancer	1.5e-05	0.000488	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—NCOR1—urinary bladder cancer	1.48e-05	0.000482	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—GSTM1—urinary bladder cancer	1.48e-05	0.000482	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—FGFR3—urinary bladder cancer	1.43e-05	0.000466	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—GPX1—urinary bladder cancer	1.42e-05	0.000462	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—ERCC2—urinary bladder cancer	1.39e-05	0.000453	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—EP300—urinary bladder cancer	1.38e-05	0.000451	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—SRC—urinary bladder cancer	1.35e-05	0.000439	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.34e-05	0.000435	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.32e-05	0.000431	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—MTHFR—urinary bladder cancer	1.31e-05	0.000426	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—GSTP1—urinary bladder cancer	1.3e-05	0.000425	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.28e-05	0.000418	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.26e-05	0.000411	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—CREBBP—urinary bladder cancer	1.22e-05	0.000396	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—TYMS—urinary bladder cancer	1.21e-05	0.000395	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—GSTM1—urinary bladder cancer	1.2e-05	0.00039	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—NCOR1—urinary bladder cancer	1.2e-05	0.00039	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—GPX1—urinary bladder cancer	1.15e-05	0.000374	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—ERCC2—urinary bladder cancer	1.13e-05	0.000367	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—KRAS—urinary bladder cancer	1.11e-05	0.000363	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—RHOA—urinary bladder cancer	1.1e-05	0.000359	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—PPARG—urinary bladder cancer	1.06e-05	0.000346	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—MTHFR—urinary bladder cancer	1.06e-05	0.000345	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—PTGS2—urinary bladder cancer	1.05e-05	0.000342	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—CREBBP—urinary bladder cancer	1.02e-05	0.000332	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—ERBB2—urinary bladder cancer	1.02e-05	0.000332	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—TP53—urinary bladder cancer	9.91e-06	0.000323	CbGpPWpGaD
Magnesium salicylate—ALB—Hemostasis—HRAS—urinary bladder cancer	9.48e-06	0.000309	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—PTEN—urinary bladder cancer	9.17e-06	0.000299	CbGpPWpGaD
Magnesium salicylate—PTGS1—Metabolism—EP300—urinary bladder cancer	8.74e-06	0.000285	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—CDKN1A—urinary bladder cancer	8.71e-06	0.000284	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—PTEN—urinary bladder cancer	8.69e-06	0.000283	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—PPARG—urinary bladder cancer	8.58e-06	0.00028	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—EP300—urinary bladder cancer	8.29e-06	0.00027	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—CREBBP—urinary bladder cancer	8.24e-06	0.000269	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—SRC—urinary bladder cancer	8.06e-06	0.000263	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—PTEN—urinary bladder cancer	7.28e-06	0.000237	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—MYC—urinary bladder cancer	7.22e-06	0.000235	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—EGFR—urinary bladder cancer	7.06e-06	0.00023	CbGpPWpGaD
Magnesium salicylate—PTGS2—Metabolism—EP300—urinary bladder cancer	6.94e-06	0.000226	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—PTGS2—urinary bladder cancer	6.75e-06	0.00022	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—KRAS—urinary bladder cancer	6.67e-06	0.000217	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—PTEN—urinary bladder cancer	5.89e-06	0.000192	CbGpPWpGaD
Magnesium salicylate—PTGS2—Disease—HRAS—urinary bladder cancer	5.67e-06	0.000185	CbGpPWpGaD
Magnesium salicylate—ALB—Metabolism—EP300—urinary bladder cancer	5.61e-06	0.000183	CbGpPWpGaD
